Heidi Vanderbrook
Family · Dallas, TXNPI 1205183407
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations.
Across 64 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$294
- AstraZeneca$130
- Viiv Healthcare Company$129
- Lilly USA, LLC$126
- AbbVie$100
- Otsuka America Pharmaceutical, Inc.$88
- plus $394 from 14 others
What the payments were for
- Food & beverage$1,261100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $294 |
| AstraZeneca | 7 | $130 |
| Viiv Healthcare Company | 5 | $129 |
| Lilly USA, LLC | 7 | $126 |
| AbbVie | 5 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $88 |
| Idorsia Pharmaceuticals US Inc | 3 | $65 |
| Pfizer | 2 | $49 |
| Tolmar, Inc. | 2 | $39 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Abbott | 1 | $25 |
| Theratechnologies Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Amgen | 1 | $14 |
How this compares
$1,261 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $40,629 |
| JardianceEmpagliflozin | 14 | $16,930 |
| FarxigaDapagliflozin Propanediol | 11 | $5,852 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 19 | $560 |
| Rosuvastatin Calcium | 30 | $420 |
| Atorvastatin Calcium | 22 | $278 |
| Losartan Potassium | 12 | $239 |
| Torsemide | 13 | $148 |
| Amlodipine Besylate | 18 | $96 |
| Metformin Hcl | 15 | $75 |
| Azithromycin | 17 | $72 |
| Lisinopril | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $294 | $40,62935 claims |
| AstraZenecaFarxiga | $130 | $5,85211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.
Other family in Dallas
- David WeirDallas$959K
- Sie ThomasDallas$197K
- Marcia HarrisDallas$156K
- Miles HortonDallas$72K
- Natasha SimmonsDallas$38K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.